[1] HEMBERGER M, HANNA CW, DEAN W. Mechanisms of early placental development in mouse and humans. Nat Rev Genet. 2020;21(1):27-43.
[2] TU X, ZHANG QR, ZHANG W, et al. Single-cell data-driven mathematical model reveals possible molecular mechanisms of embryonic stem-cell differentiation. Math Biosci Eng. 2019;16(5):5877-5896.
[3] D’SOUZA GX, ROSE SE, KNUPP A, et al. The application of in vitro-derived human neurons in neurodegenerative disease modeling. J Neurosci Res. 2020 Mar 13. doi: 10.1002/jnr.24615. Online ahead of print.
[4] SAMAK M, HINKEL R. Stem Cells in Cardiovascular Medicine: Historical Overview and Future Prospects. Cells. 2019;8(12):1530.
[5] DANIEL MG, RAPP K, SCHANIEL C, et al. Induction of developmental hematopoiesis mediated by transcription factors and the hematopoietic microenvironment. Ann N Y Acad Sci. 2020;1466(1):59-72.
[6] DEGUCHI S, TAKAYAMA K, MIZUGUCHI H. Generation of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells for Cellular Medicine. Biol Pharm Bull. 2020;43(4):608-615.
[7] ALAVI M, BARANOV P. The iPSc-Derived Retinal Tissue as a Tool to Study Growth Factor Production in the Eye. Adv Exp Med Biol. 2018;1074:619-624.
[8] MIRANDA CC, FERNANDES TG, DIOGO MM, et al. Human Pluripotent Stem Cells: Applications and Challenges for Regenerative Medicine and Disease Modeling. Adv Biochem Eng Biotechnol. 2020;171:189-224.
[9] TAKAHASHI K, YAMANAKA S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4): 663-676.
[10] ISHINO Y, SHINAGAWA H, MAKINO K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169(12):5429-5433.
[11] HSU PD, LANDER ES, ZHANG F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-1278.
[12] OKITA K, ICHISAKA T, YAMANAKA S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313-317.
[13] YOSHIDA Y, YAMANAKA S. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res. 2017;120(12):1958-1968.
[14] WEN W, ZHANG JP, CHEN W, et al. Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors. J Vis Exp. 2017;(119):55091.
[15] WANG L, SU Y, HUANG C, et al. NANOG and LIN28 dramatically improve human cell reprogramming by modulating LIN41 and canonical WNT activities. Biol Open. 2019;8(12):bio047225.
[16] LIU J, HAN Q, PENG T, et al. The oncogene c-Jun impedes somatic cell reprogramming. Nat Cell Biol. 2015;17(7):856-867.
[17] AL ABBAR A, NORDIN N, GHAZALLI N, et al. Generation of induced pluripotent stem cells by a polycistronic lentiviral vector in feeder- and serum- free defined culture. Tissue Cell. 2018 ;55:13-24.
[18] LEE CH, INGROLE RSJ, GILL HS. Generation of induced pluripotent stem cells using elastin like polypeptides as a non-viral gene delivery system. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165405.
[19] SLAMECKA J, SALIMOVA L, MCCLELLAN S, et al. Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions. Cell Cycle. 2016;15(2):234-249.
[20] TAI L, TEOH HK, CHEONG SK. Reprogramming human dermal fibroblast into induced pluripotent stem cells using nonintegrative Sendai virus for transduction. Malays J Pathol. 2018;40(3):325-329.
[21] MCGRATH PS, DIETTE N, KOGUT I, et al. RNA-based Reprogramming of Human Primary Fibroblasts into Induced Pluripotent Stem Cells. J Vis Exp. 2018; (141): 10.3791/58687.
[22] HEW BE, SATO R, MAURO D, et al. RNA-guided piggyBac transposition in human cells. Synth Biol (Oxf). 2019;4(1):ysz018.
[23] CHEN G, GUO Y, LI C, et al. Small Molecules that Promote Self-Renewal of Stem Cells and Somatic Cell Reprogramming. Stem Cell Rev Rep. 2020;16(3):511-523.
[24] KIM C. Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application. Blood Res. 2014;49(1):7-14.
[25] WEN WS, YUAN ZM, MA SJ, et al. CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies. Int J Cancer. 2016;138(6): 1328-1336.
[26] BATLLE E, CLEVERS H. Cancer stem cells revisited. Nat Med. 2017;23(10): 1124-1134.
[27] CHAO HM, CHERN E. Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research. J Formos Med Assoc. 2018;117(12): 1046-1057.
[28] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
[29] DASGUPTA P, HENSHAW C, YOULDEN DR, et al. Global trends in incidence rates of childhood liver cancers: A systematic review and meta-analysis. Paediatr Perinat Epidemiol. 2020 Apr 26. doi: 10.1111/ppe.12671. Online ahead of print.
[30] ASHMORE-HARRIS C, BLACKFORD SJ, GRIMSDELL B, et al. Reporter gene-engineering of human induced pluripotent stem cells during differentiation renders in vivo traceable hepatocyte-like cells accessible. Stem Cell Res. 2019; 41:101599.
[31] WANG R, CHEN S, LI C, et al. Fusion with stem cell makes the hepatocellular carcinoma cells similar to liver tumor-initiating cells. BMC Cancer. 2016;16:56.
[32] HAN S, GUO J, LIU Y, et al. Knock out CD44 in reprogrammed liver cancer cell C3A increases CSCs stemness and promotes differentiation. Oncotarget. 2015; 6(42):44452-44465.
[33] KIDO T, KOUI Y, SUZUKI K, et al. CPM Is a Useful Cell Surface Marker to Isolate Expandable Bi-Potential Liver Progenitor Cells Derived from Human iPS Cells. Stem Cell Reports. 2015;5(4):508-515.
[34] KANEKO S, KAKINUMA S, ASAHINA Y, et al. Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Sci Rep. 2016;6:29358.
[35] ZHU P, WANG Y, DU Y, et al. C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun. 2015;6: 7122.
[36] HOFMAN P. Advances in theranostic biomarkers for lung cancer from clinical to molecular pathology. J Thorac Dis. 2019;11(Suppl 1):S1-S2.
[37] FIRTH AL, DARGITZ CT, QUALLS SJ, et al. Generation of multiciliated cells in functional airway epithelia from human induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2014;111(17):E1723-1730.
[38] GHAEDI M, MENDEZ JJ, BOVE PF, et al. Alveolar epithelial differentiation of human induced pluripotent stem cells in a rotating bioreactor. Biomaterials. 2014;35(2):699-710.
[39] KIRK R, DIPCHAND AI, ROSENTHAL DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant. 2014;33(9): 888-909.
[40] QUAN Y, WANG D. Clinical potentials of human pluripotent stem cells in lung diseases. Clin Transl Med. 2014;3:15.
[41] ASNAGHI A, MACCHIARINI P, MANTERO S. Tissue engineering toward organ replacement: a promising approach in airway transplant. Int J Artif Organs. 2009; 32(11):763-768.
[42] GUENTHART BA, O’NEILL JD, KIM J, et al. Cell replacement in human lung bioengineering. J Heart Lung Transplant. 2019;38(2):215-224.
[43] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.
[44] SATO T, VRIES RG, SNIPPERT HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244): 262-265.
[45] SINGOVSKI G, BERNAL C, KUCIAK M, et al. In vivo epigenetic reprogramming of primary human colon cancer cells enhances metastases. J Mol Cell Biol. 2016; 8(2):157-173.
[46] CONG L, RAN FA, COX D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.
[47] MATANO M, DATE S, SHIMOKAWA M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015;21(3):256-262.
[48] SASIKUMAR R, REJITHA JR, BINUMON PK, et al. Role of heterozygous APC mutation in niche succession and initiation of colorectal cancer--a computational study. PLoS One. 2011;6(8):e22720.
[49] CRESPO M, VILAR E, TSAI SY, et al. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med. 2017;23(7):878-884.
[50] DROST J, VAN BOXTEL R, BLOKZIJL F, et al. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. Science. 2017;358(6360):234-238.
[51] ROPER J, TAMMELA T, CETINBAS NM, et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol. 2017;35(6):569-576.
[52] JI Y, YANG C, TANG Z, et al. Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation. Nat Commun. 2017;8:15308.
[53] SADYKOVA LR, NTEKIM AI, MUYANGWA-SEMENOVA M, et al. Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest. 2020. doi: 10.1080/07357907.2020.1768401. Online ahead of print.
[54] LIN YH, JEWELL BE, GINGOLD J, et al. Osteosarcoma: Molecular Pathogenesis and iPSC Modeling. Trends Mol Med. 2017;23(8):737-755.
[55] MASCIARI S, DEWANWALA A, STOFFEL EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011;13(7):651-657.
[56] LEE DF, SU J, KIM HS, et al. Modeling familial cancer with induced pluripotent stem cells. Cell. 2015;161(2):240-254.
[57] HAN Y, FENG H, SUN J, et al. Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation. J Clin Invest. 2019;129(5):1895-1909.
[58] 杨鹏,冯娜,李莎莎,等.白血病患者并发肺部感染的临床分析[J].中华肺部疾病杂志(电子版),2018,11(6): 726-728.
[59] MAALI A, ATASHI A, GHAFFARI S, et al. A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future. Curr Stem Cell Res Ther. 2018;13(8):665-675.
[60] SUNDARAMURTHI T, WEHRLEN L, FRIEDMAN E, et al. Hematopoietic Stem Cell Transplantation Recipient and Caregiver Factors Affecting Length of Stay and Readmission. Oncol Nurs Forum. 2017;44(5):571-579.
[61] SALCI KR, LEE JH, LARONDE S, et al. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. Stem Cells. 2015;33(6):1839-1849.
[62] LIU Y, CHENG H, GAO S, et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia. 2014;28(5):1071-1080.
[63] KUMANO K, ARAI S, HOSOI M, et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood. 2012; 119(26):6234-6242.
[64] KOTINI AG, CHANG CJ, CHOW A, et al. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017;20(3):315-328.e7.
[65] XU L, WANG J, LIU Y, et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. N Engl J Med. 2019;381(13):1240-1247.
|